Table 1. Clinical and histopathological details for patient samples used in the study.

Patient	Histology	Age	Status	FIGO stage	Grade	LVS involved	Tamoxifen use
1	Benign	51	Alive	—	—	—	N
2	Benign	57	Alive	—	—	—	N
3	Benign	80	Alive	—	—	—	N
4	Benign	63	Alive	—	—	—	N
5	Benign	68	Alive	—	—	—	N
6	ACH	56	Alive	—	—	—	N
7	ACH	58	Alive	—	—	—	N
8	ACH	52	Alive	—	—	—	N
9	ACH	69	Alive	—	—	—	N
10	ACH	52	Alive	—	—	—	N
11	Endometrioid cancer	41	Alive	1C	1	N	N
12	Endometrioid cancer	56	Alive	2B	2	N/R	N
13	Endometrioid cancer	48	Alive	2B	2	Y	N
14	Endometrioid cancer	46	Alive	1B	2	N	N
15	Endometrioid cancer	71	Alive	3A	3	N/R	N
16	Endometrioid cancer	87	Alive	1B	3	N	N
17	Endometrioid cancer	54	Alive	1B	3	N	Y
18	Endometrioid cancer	78	Deceased	1C	3	N	N
19	Endometrioid cancer	84	Deceased	4A	3	Y	N
20	Endometrioid cancer	56	Alive	3B	3	N/R	N
21	Endometrioid cancer	52	Alive	1B	3	N/R	Y
22	Endometrioid cancer	68	Deceased	4A	3	Y	Y
23	Endometrioid cancer	81	Alive	1B	3	Y	N

ACH=atypical complex hyperplasia; LVS=lymphovascular space involvement N/R=not reported N=never, Y=yes.